livmoniplimab   Click here for help

GtoPdb Ligand ID: 11762

Synonyms: 39B6-AYE [1] | ABBV-151 [1] | ARGX-115 | ARGX115 | MHG-8 | MHGARP-8 | PR-1762844
Compound class: Antibody
Comment: Livmoniplimab (ABBV-151, formerly ARGX-115 and MHG-8) is a chimeric, humanised IgG4-κ monoclonal antibody that targets LRRC32 (GARP)/transforming growth factor β1 (TGFβ1) complexes. It blocks LRRC32-mediated activation of latent TGFβ1, and was designed to block immunosuppressive Treg activity in tumours, as an immunooncology strategy.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Livmoniplimab (ABBV-151) has been advanced to early stage clinical evaluation in solid tumours.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03821935 Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors Phase 1 Interventional AbbVie Budigalimab (ABBV-181) is an anti-programmed cell death 1 (PD-1) monoclonal.